OP Asset Management Ltd Acquires New Stake in Solventum Corporation $SOLV

OP Asset Management Ltd bought a new position in shares of Solventum Corporation (NYSE:SOLV) during the 1st quarter, HoldingsChannel.com reports. The institutional investor bought 16,419 shares of the company’s stock, valued at approximately $1,072,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Assetmark Inc. increased its position in shares of Solventum by 21.4% during the 4th quarter. Assetmark Inc. now owns 725 shares of the company’s stock valued at $57,000 after purchasing an additional 128 shares during the period. Hilltop National Bank lifted its holdings in shares of Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after buying an additional 129 shares during the period. Allworth Financial LP boosted its stake in Solventum by 2.8% during the third quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock valued at $350,000 after buying an additional 129 shares in the last quarter. CIBC Private Wealth Group LLC boosted its stake in Solventum by 0.5% during the third quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock valued at $1,804,000 after buying an additional 134 shares in the last quarter. Finally, BOKF NA boosted its stake in Solventum by 6.9% during the third quarter. BOKF NA now owns 2,193 shares of the company’s stock valued at $160,000 after buying an additional 141 shares in the last quarter.

Solventum Trading Down 1.7%

NYSE:SOLV opened at $78.21 on Tuesday. The stock has a fifty day simple moving average of $74.76 and a 200 day simple moving average of $74.55. The firm has a market capitalization of $13.54 billion, a price-to-earnings ratio of 9.58, a price-to-earnings-growth ratio of 1.23 and a beta of 0.69. Solventum Corporation has a 1-year low of $62.38 and a 1-year high of $88.20. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the previous year, the company earned $1.34 EPS. The business’s revenue for the quarter was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Sell-side analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on SOLV shares. Stifel Nicolaus dropped their price target on shares of Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Wedbush started coverage on shares of Solventum in a research report on Friday, May 15th. They set an “outperform” rating and a $94.00 price objective for the company. Piper Sandler lowered their price objective on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Rothschild & Co Redburn began coverage on shares of Solventum in a report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 target price on the stock. Finally, BTIG Research reissued a “buy” rating and set a $89.00 target price on shares of Solventum in a research note on Wednesday, May 6th. Eight investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $84.25.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.